Genentech received approval from the FDA to market Actemra, or tocilizumab, for children 2 and older with active polyarticular juvenile idiopathic arthritis. The drug, a humanized interleukin-6 receptor antagonist, can be given alone or with methotrexate. The approval was based on data from a late-stage trial showing that the drug improved symptoms in children with the condition.
FDA expands use of Genentech's Actemra to include polyarticular JIA
SmartBrief Job Listings for Health Care
|Senior Research Analyst||
America's Health Insurance Plans (AHIP)
|Manager, Regulatory Affairs||
|Washington DC, DC|
|Senior Counsel - FDA Regulatory Affairs||
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|